Celdara Medical, LLC news

Celdara Medical, LLC (CM) is developing a portfolio of preclinical therapeutic assets, platforms, and companies. Each of these has a different development path, and we work with many different modalities, and in many different indications, but everything we do is singularly focused on saving lives and/or improving quality of life.

CM is seeking a seasoned life science professional to lead programs (organized as small business units or “companies-in-waiting”) as part of the

January 26, 2022 – Aclys Bio Corp (“Aclys”), a company discovering and developing precision biologics for the treatment of cancer, earlier this month announced a new exclusive research and commercial license option agreement with Genmab A/S (Nasdaq: GMAB), an international biotech company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.

Under the terms of the agreement, Genmab secures exclusive rights t

February 22, 2022 – Celdara Medical, LLC today announced that alumni of their DRIVEN Partnership Program have collectively surpassed $50M in follow-on funding. DRIVEN was established in 2018 as the Northeast’s NIH-funded Accelerator Hub. Led by Celdara Medical and Simbex, it has always had a singular goal: improve human health by increasing the number, quality, and success rate of biomedical startups.

DRIVEN is engaged with partners representing every major resear

Celdara Medical seeks outstanding scientists with interest in translational research and biotechnology for a paid Fellowship